Trials / Conditions / Von Willebrand Disease (VWD)

Von Willebrand Disease (VWD)

15 registered clinical trials studyying Von Willebrand Disease (VWD) — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate NCT07410130	Assiut University	—
Recruiting	An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD) NCT07404644	Takeda	—
Recruiting	Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD) NCT07115004	Vega Therapeutics, Inc	Phase 3
Recruiting	A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) NCT07129343	Takeda	Phase 3
Not Yet Recruiting	Algorithm-based Management to Reduce the Recurrence of GI Bleeding and Severe Epistaxis in Von Willebrand Dise NCT06651255	University Hospital, Lille	N/A
Recruiting	A Study Assessing HMB-002 in Participants With Von Willebrand Disease NCT06754852	Hemab ApS	Phase 1 / Phase 2
Recruiting	A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD) NCT05582993	Takeda	Phase 3
Recruiting	A Study of Bleeding and Treatment in Participants With Von Willebrand Disease NCT06610201	Hemab ApS	—
Completed	T-TAS® wS Method Comparison NCT06710262	Hikari Dx, Inc.	—
Recruiting	Endothelial Colony-Forming Cells in Patients With VWD, AVWS and Healthy Subjects NCT07358013	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	—
Completed	A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Th NCT05695560	Takeda	—
Completed	A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With NCT05265078	Takeda	—
Completed	A Study on the Outcomes of Recombinant Von Willebrand Factor on Demand Treatment and Prevention and Treatment NCT06433778	Takeda	—
Completed	A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willeb NCT03879135	Baxalta now part of Shire	Phase 3
Available	Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD) NCT06173024	Takeda	—